A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Methotrexate (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMMENCE
- 03 May 2019 Planned End Date changed from 1 Feb 2018 to 1 Dec 2020.
- 03 May 2019 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2019.
- 23 Oct 2018 OS and detailed toxicity results will be presented later, as reported in an abstract presented at the 43rd European Society for Medical Oncology Congress